CDC states (www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#timing-spacing-interchangeability) that a person who moves to an older age group between vaccine doses should receive the vaccine product and dosage for the older age group for all subsequent doses.
Children who initiated their primary series with Pfizer-BioNTech brand products and turn age 5 years during the primary series have two options:
- Receive a single dose of updated (2023–2024 Formula) Pfizer-BioNTech COVID-19 Vaccine, 0.3 mL/10 mcg (blue cap; blue label) on or after turning age 5 years. If the 10 mcg dose is the second dose, administer 3–8 weeks after the first dose; if it is the third dose, administer at least 8 weeks after the second dose, OR
- Complete the 3-dose series with updated (2023–2024 Formula) Pfizer-BioNTech COVID-19 Vaccine for ages 6 months–4 years, 0.3 mL/3 mcg (yellow cap; yellow label), as outlined in the FDA EUA.